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Obrcsives. This analysis aimed to evaluate in a large patient
cohort the relation between ST segment alterations after fibrino-
lytic therapy for acute myocardial infarction and 1) the combined
end point of in-hospital mortality plus clinical congestive heart
failure or extensive left ventricular damage, and 2) mortality 30
and 180 days after randomization .
Ba *pmh,A Angina relief, enzyme release acceleration and ST
segment normalization are related to coronary artery reperlirsion
and prognosis. Electrocardiographic (ECG) evaluation before and
after fibrinolytic drug administration has been used to predict short-
and long-term clinical outcome in acute myocardial infarction .
Methods. Patients enrolled in the Gruppo Italian per lo Studio
della Sopravvivenza nell'lnfarto Miocardico (GISSI-2) trial un-
derwent a standard ECG on admission vnd after 4 h of alteplase
or streptokinase therapy; 7,426 recordings were suitable for ST
segment analysis. A decrease X50% in the sum of ST segment
elevation in all ECG leads was adopted as the cutoff for predicting
coronary artery potency. Recanalization was deemed to have
The most significant advance in the management of acute
myocardial infarction during the past 10 years has been the
introduction of thrombolysis in routine clinical practice.
Thrombolytic treatment has been shown to reduce infarct size
and improve left ventricular function and survival rate by
reopening the infarct-related coronary artery . However, the
interdependence and prognostic significance of the chain of
events that may follow the administration of a thrombolytic
agent in patients with acute myocardial infarction remain
unclear. In 20% to 40% of patients, recanalization of the
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occurred in 4,951 patients (group A) versus 2,475 patients without
reperfusion (group B).
Results. Group A patients experienced a lower incidence of the
combined end point than did group B patients (16.2% vs. 22.9%,
respectively), as well as of all its components (death, clinical heart
failure, ejection fraction <35%, injured myocardial segment >45%,
QRS score >10). Thirty- and 1 y mortality rates were lower in
group A than group B (3.5%and 5.7% vs. 7,4% and 9,9%, respective-
ly); relative risk (Cox) was 0.46 (95% confidence interval ICI] 0 .37 to
0.57) for 30-clay and 0.58 (95% Cl 0.48 to 0.70) for 180-day mortality.
Patients in group A had significantly less ventricular fibrillation and
sustained ventricular tachycardia but more ischemic episodes (early
recurrent angina plus myocardial infarction recurrence) .
Conclusions. A simple, inexpensive instrumental evaluation, un-
affected by different epidemiologic and clinical characteristics of the
population analyzed, can allow early assessment of the effectiveness
of fibrinolytic treatment with respect to the main clinical outcomes .
(J Am Coll Cardiol 1994;24
:600-7)
infarct-related coronary artery does not occur, and in 15% to
20%, the open vessel reoceludes ; these events affect in-hospital
and long-term prognosis .
Coronary reperfusion relieves pain and accelerates enzyme
release and ST segment normalization (1-4), and these clinical
and instrumental signs have been shown to be related to
coronary artery recanalization and prognosis (5,6). Hence, the
availability of early, simple and inexpensive reperfusion-
related prognostic indicators could be helpful in subsequent
therapeutic decision making . In the setting of a large-scale
clinical trial (GISSI-2), designed to compare the benefit/risk
profile of alteplase and streptokinase with or without subcuta-
neous heparin (7), a sequential electrocardiographic (ECG)
evaluation was planned to study whether an early reduction in
ST segment elevation was associated with a more favorable
outcome and to analyze the relation between early resolution
of ST segment elevation and the clinical characteristics of the
patients .
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Figure 1 . Diagram of reasons for exclusion from this study of patients
enrolled in the GISSI-2 trial. AMI -- acute myocardial infarction ;
ECG ° electrocardiogram ; MI myocardial infarction .
Methods
Patient population . Details of the design and main results
of the GISSI-2 trial are available in the original report (7) . In
brief, patients of any age were eligible for randomization if
they presented to the participating coronary care units within
6 h of the onset of symptoms . had no clear contraindications to
thrombolytic therapy and had ECG signs of at least 1-mm ST
segment elevation in two limb leads or 2 mm in at least one
precordial lead .
A total of 12,490 patients were randomized to receive
streptokinase (1 .5 MU over °y) to 60 min) or tissue-type plasmin-
ogen activator (t-PA [alteplase]) (100 ntg over 3 h), with or
without subcutaneous heparin (12,50) U twice daily) . The analy-
sis presented here concerns 7,426 patients (--60% of the whole
population) . The criteria for exclusion of the remaining 5,064
patients from this analysis are displayed in Figure 1 : Clinical
records were not available for 109 (0 .8%) patients; the 4-h ECG
was not recorded in 1,695 patients (13.6%), either because the
patient had died or because of organizational problems ; the
diagnosis of acute myocardial infarction was not confirmed in 898
patients (7.2%), and in 2,362 patients (18.9%) a history of
previous myocardial infarction (1,763 patients) or the presence of
bundle branch block (599 patients), or both could have prevented
the accurate evaluation of ST segment elevation .
Electrocardiographic analysis . A standard ECG plus V3R
and V4R leads was recorded before randomization, 4 h after
the beginning of thrombolytic infusion and before hospital
discharge. All of the ECGs were separately evaluated by four
expert cardiologists unaware of the allocated treatment, who
were asked to record the presence of a pathologic Q wave
(lasting >30 ms), the sum of ST segment elevation in all leads
(total ST segment elevation) and the QRS score (8) for each
tracing . The site and extent of infarction were defined accord-
ing to previously described criteria (7-9). ST segment elevation
in V3R and V4R leads was used to define right ventricular
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involvement and the extent of the infarct . The difference
between total ST segment elevation at randomization and after
4 h was calculated for all tracings as the percent decrease
. In
accord with the guidelines of Bossaert et al . (10), a decrease in
total ST segment elevation >50% was adopted as the cutoff
value for predicting noninvr eve coronary reperfusion and
prognosis .
Clinical evaluation. The demographic characteristics of
the patients, previous clinical history and any clinically relevant
events occurring during the hospital stay (including left ven-
tricular failure and severe arrhythmic episodes) were recorded
on the study form. The participating coronary 'Ire units were
also requested to record any clinically relevant =vents (death,
reinfaretion, cerebrovascular accident) occurring in their pa-
tients during the 1st 6 months after randomization .
Creatine kinase (CK) serum levels were measured at 3-h
intervals for 24 It and then every 8 It up to the end of the third
day after the onset of symptoms ; the peak CK value and time
to peak CK were recorded .
The main end points of the analysis were to study the
relations between ST segment resolution and 1) the combined
end point of in-hospital mortality plus clinical congestive heart
failure (after day 4 but before discharge) or extensive left
ventricular damage at discharge (the definition of the criteria
of left ventricular failure and the hierarchic use of the indexes
of severe left ventricular damage as end points have been
reported elsewhere [ I 11) ; 2) mortality at 30 days after random-
ization; 3) mortality at 180 days after randomization .
Statistical analysis . The distribution of baseline character-
istics in the two groups of patients with or without an early
decrease }50% in total ST segment elevation was assessed
using standard chi-square tests . The frequency of major clinical
events as a function of early ECG changes are presented in
terms of the Mantel-Hacnszcl odds ratio and 95% confidence
interval (12). The Cox proportional hazard model (13) was
used to adjust the relation between 30-day and 6-month
mortality and total ST segment elevation resolution according
to the main demographic and clinical features. The following
factors were included in the model : age, gender, a history of
insulin-dependent diabetes or treated hypertension, the time
from the onset of symptoms to thrombolytic treatment, Killip
class at admission, heart rate and systolic blood pressure at
entry, the number of ECG leads showing ST segment elevation
and total ST segment elevation at entry and allocated treat-
ments. The results of the adjusted analysis are reported as risk
ratios (Cox) and 95% confidence intervals .
Results
Baseline characteristics and ECG changes. Within 4 h of
the start of thrombolytic therapy, total ST segment elevation
was decreased ?50% in 4,951 patients (66 .7%, group A) and
<50% or not at all in 2,475 patients (33 .3%, group B) (Table
1). Patients in group A were more often current smokers, were
nondiabetic, had been treated within 3 h of symptom onset,
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Table 1. Distribution of Demographic, Clinical and Therapeutic
Variables in the Two Study Groups
BP
-
blood pressure
; HR = heart rate
; ID = insulin dependent; Pts =
patients
; SK = strepokinase
; t-PA = tissue-type plasminogen activator; EST =
total ST segment elevation .
were in Killip class I, had an inferior infarction and a greater
extent of infarct and had been treated with streptokinase .
Table 2 shows the proportion of patients with an early decrease
in total ST segment elevation . The odds ratio demonstrates the
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chance that a single characteristic is associated with early ST
segment resolution compared with the reference category .
Patient age and gender did not affect early ST segment
resolution : among the 1,469 patients >70 years old (19 .8% of
the whole study population), the proportion of patients with an
early decrease in ST segment elevation was 66 .2%, similar to
that observed among younger patients . Of the 1,477 women
(19.9% of the whole cohort), 978 (66.2%®) showed a decrease in
ST segment elevation >_50%, similar to that observed for men
(66.8%). Current smoking habit appeared to be associated
with a slightly higher frequency of early decrease in ST
elevation, as was found in 67% of current smokers and in
64.1% of nonsmokers. No difference was observed in plasma
cholesterol level, previous history of treated hypertension or
previous history of angina . In 138 patients with insulin-
dependent diabetes there was a lower frequency of decrease in
total ST segment elevation X50%® (55 .8% vs. 66.9%) than in
nondiabetic patients.
An early reduction in total ST segment elevation was
observed in 67.5% of patients treated within 3 h of symptom
onset and in 64.5% of patients treated between 3 and 6 h of
symptom onset. The proportion of patients without ECG signs
predictive of reperfusion increased significantly with their
Killip class : 32.5% of patients in Killip class I, to 38 .4% in class
Il, to 41 .4% in class III, to 43.3% in class IV .
Among the 2,686 patients with an anterior infarction,
58.1% had early reduction in total ST segment elevation
compared with 69.6% of patients with a multisite infarction,
72.5% with a lateral infarction and 75 .1% with an inferior
infarction . Favorable ST segment resolution was more fre-
quent among patients with a larger myocardial infarction :
59.3% in patients with fewer than four leads showing ST
segment elevation at randomization, 66% in patients with four
or five leads, 72.3% in patients with six or seven leads, and
71.5% in the 445 patients with more than eight leads involved.
Patients with a larger extent of myocardial infarct, as measured
by total ST segment elevation (i.e ., >0.6 mV), had the same
favorable ST segment resolution (Tables 1 and 2) .
Heart rate and systolic blood pressure at randomization did
not appear to affect the resolution of ST segment elevation .
Among the 3,660 patients treated with streptokinase, 70.1%
had a decrease >50% in total ST segment elevation on
standard ECG leads 4 h after the beginning of thrombolysis,
whereas only 63 .3% of the 3,766 t-PA-treated patients showed
a similar pattern. This difference was statistically significant .
Among the 7,414 serum CK curves available, peak levels within
12 h of symptom onset were observed in 4,617 patients (62 .2%
of the whole population) : 65.9% in group A versus 54 .9% in
group B (p < 0 .001).
Electrocardiographic changes and major clinical events .
The main clinical events occurring during the hospital stay are
reported in Table 3 by ST segment resolution. Compared with
patients in group B, those in group A patients had a signifi-
cantly lower incidence of ventricular fibrillation (p < 0 .0002)
and sustained ventricular tachycardia (p < 0 .03). No difference
was seen in the incidence of major atrioventricular block. The
Group A
(n = 4,951)
Group B
(n = 2,475)
No. of
Pts %
No. of
Pts %
p
Value
Age >70 (yr) 972 19.6
497
20.1
NS
Female gender
978 19.8 499 20.2 NS
S
Past
974 19.7 479 19.4 NS
Present 2,746 55.5 1,305 52.7
< 0.05
Treated hypertension
Yes 1,385 28.6 684 27.6 NS
Unknown 299 6.0
149 6.0 NS
Hypercholesterolemia
Yes 1,125 22.7
542 21 .9 NS
Unknown 1,394
28.2 690 27 .9 NS
ID diabetes
Yes 77 1 .6
61 2.5 < 0.01
Unknown 267 5 .4 132 5.3 NS
History of angina
871) 17 .6 432
17.5
NS
Time to fibrinolysis
s3 h 3,580 72 .4
1,720 69.6 < 0.0025
>3-6 h 1,368 27.6 753
30
.4 < 0 .0025
Killip class
1
4,122 83.3 1,949 68.8 < 0 .001
11 734 14.8 458 18.5 < 0 .001
111
78 1.6 55 2
.2
< 0
.05
IV 13 0.3 17 0.5 NS
Infarct site
Anterior 1,565 31 .6 1,121 • 45 .3 < 0.001
Inferior
2,328 47.0 775 31 .3 < 0.001
Lateral 153 3.1 58 2
.3
NS
Multisite 429 8.7 187 7.6 NS
Other 476 9.6 334
13.5 < 0.001
ST segment elevation
a3 leads 1,109
22 .4 762 30 .8 < 0.001
4-5 leads 1,782 36.0 917 37.1 NS
6-7 leads
1,615 32 .6 619 25.0 < 0.001
ar8 leads 445 9 .0 177 7
.2 < 0.01
EST (mV)
s0.6
1,686 34
.1 1,110
44.8 < 0.001
0.6-1.2 1
.611 32.5 801 32.4
NS
>1 .2
1,654 33.4 564 22.8 < 0.001
HR (beats/min)
<60
832 16.8 423 16.1 NS
60-100
3,820
77
.2 1,892 76.4 NS
>100
299 6.0 160 6
.5 NS
Systolic BP (mm Hg)
< 100
260 5.3 126
5.1 NS
100-150
3,594 72.5 1,796 72.6
NS
>150 1,097
22.2 553 22.3 NS
Treatment
SK
2,567 51 .8 1,093 44 .2
< 0.001
t-PA
2,384 48.2
1,.382 55 .8 < 0.001
Heparin
2,479 50.1 1,224 49
.5 NS
No heparin 2,472 49.9
1,251 50 .5 NS
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Table 2. ST Segment Resolution by
Demographic, Clinical and Therapeutic Variables
Abbreviations as in Table 1 .
Decrease in Total ST
Segment Elevation }50%
Total No.
of Pis
No . of
Pis
Odds
Ratio
95% Confidence
Interval
Age (r)
570
5,957 3,979 66.8
1
>70 1,469
972 66
.2
0.97
0 .86-1 .09
Gender
Male 5,949 3,973 66
.8 1
Female 1,477 9E 66
.2 0.97 0AQ.10
Smoking
Never
1,922 1,231 64.1 1
Past 1A3 974
67.0 1 .14 0 .99-1 .22
Present 4,051 2,746
67.8 1 .18 1 .05-1 .33
Treated hypertension
No
4.999
3,267 66.6
1
Yes
2,00
9 1,385 00.9 1 .02
0 .91-1 .13
Unknown
448
299
063 1 .01 0
.82-1 .24
I lypercholesterolemia
No 3,675 2,432 66
.2 1
Yes 1,667 1,125
67.5
1 .06
0 .94-12(1
lJoknown 2,084 1 .394 60 .9 1 .03 0 .92-1 .16
ID diabetes
No 6,889 4,607 66.9 1
Yes 138 77 55 .8 0.61 0.42-0.87
Unknown
399
20 66 .9
1.00
0 .81-1 .28
History of angina
No 6,124 4,1(81 66.6 1
Yes 1,302 870 66 .8 1 .01 0 .89-1 .45
Time to fibrinolysis
5311
5 .3(1(1
3,580 67 .5 1
3-6 h 2,121 1,368
64
.5 0 .87 11 .78-0.97
Killip class
1 6,071 4,122 67 .9 1
11 1,192 734 61 .6 (1 .75 0 .66-0,86
III 133 78 58 .6
(( .65
11 .45-0.45
IV 30 13 56 .1
0
.32 11
.15-0
.70
Infarct site
Anterior 2,686 1,565 58 .1 1
Inferior
3,103 2,328 75 .1 2 .14 1 .92-2 .38
Lateral
211 153 72 .5 1
.8(1
1 .35-2
.4(1
Multisite 616 429 69 .6
1 .61
1 .34-1
.92
Other
810 479 59 .1
1 .1)3 0.88-1 .21
ST segment elevation
WARs 1,871
1 ' 109
59 .3
1
4-5 leads 2,699
1,782
66 .0
1 .34 1 .18-1 .51
6-7 leads 2,234
1M5 72 .3 1 .79 1 .57-2 .04
?8 leads
622 445 71 .5 1 .69 1
.40-2 .03
EST (MV)
<(1,6 2,796 1,686 6(1.3
1
0A-1 .2 2,412 1,611 66
.8 1 .32 1 .18-1 .48
>1 .2 2,218 1,654 74 .6
1 .90 1 .69-2 .14
HR (hwWmW)
<60 1,255
423 33 .7 1
60-100 5,712
1,892 33 .1
1M3 OMPLI7
A(M) 459
160 34 .9
0.95 0 .76-1 .19
Systolic BP (mm Hg)
<100
386 126 32.6
1
109-150
5,39(1 3,594 66.7
0 .97 0 .78-1 .21
>150
1,650 1,097 66.5
0.96
0,76-1 .22
Treatment
SK
3,660
1,093 29.9 1
SEA
3,766 Is82
36 .7 033
06-1181
Heparin 3,703
1224 33.1
1
No heparin 3,723
2,472 66.4
0.98 0 .89-1 .07
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Table 3. Main Clinical In-Hospital Events by ST Segment Resolution
recurrence of myocardial ischemia was cumulatively (p <
0.0001) more frequent in group A patients than in those in
group B (2 .1% and 1.9% for myocardial infarction ; 10.4% vs.
7.8°/a for early post infarction angina, respectively) .
The incidence of the combined end point of in-hospital
mortality plus congestive heart failure or left ventl'icular
damage at discharge (adopted in the GISSI-2 study to compare
the efficacy of the different thrombolytic and antithrombotic
regimens) was significantly lower among patients with early ST
segment resolution. 16.2% in group A versus 22 .9% in group B
(p < 0.0001). Moreover, group A patients experienced a lower
incidence of each of the single events making up the cumula-
tive end point (Table 4). The in-hospital mortality rate appears
to be directly related to the percent decrease in total ST
segment elevation recorded 4 h after symptom onset (Fig . 2)
because it was 11.7% in patients with < 10% reduction in total
ST segment elevation and progressively decreased to 3 .2% in
patients with a total regression of ST segment elevation . The
difference was more significant in patients with large infarct
(more than six leads involved in ST segment elevation) than in
those with a; small infarct. The mortality rate was 17.6% in 262
patients with a large infarct and no significant change in total
ST segment elevation at the 4-h ECG and 3.2% in 434 patients
with regression of total ST segment elevation to the isoclectric
line ; it was 11 .7% in 855 patients with a small infarct without
reduction in total ST segment elevation and 3 .2% in 1,382
patients with an isoelectric ST segment at the 4-h ECG .
(1 .1471 .593)
Date presented are number (%) of patients. AV = atrioventrieular ; CI = confidence interval .
Table 4. Combined End Point at Discharge (mortality and congestive heart failure or severe left
ventricular damage) by ST Segment Resolution
Data presented are number (%) of patients
. EF = ejection fraction
; Cl = confidence interval .
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The mortality rate 30 days after symptom onset was 3 .5%
(173 patients) in group A versus 7 .4%p (184 patients) in group
B (p < 0.0001), a slight difference from the rates observed at
discharge. The adjusted analysis confirms that a reduction in
total ST segment elevation y50°* 4 It after fibrinolysis is an
independent predictor of death within 39 days of the onset of
acute myocardial infarction (relative risk [Cox] 0 .46; 95%
confidence interval [Cl] 0 .37 to 0.57) . Survival analysis showed
that the benefit persisted at 6 months, with a mortality rate of
5.7% (283 patients) in group A versus 10% (247 patients) in
group B (Fig. 3). The difference was substantially unchanged
when adjusted for the other previously listed prognostic vari-
ables (relative risk [Cox] 0.58-,95% Cl 0.48 to 0.70) .
Discussion
Angi phic and clinical meaning of ST segment resolu-
tion. Continuous ECG monitoring early in myocardial infarc-
tion shows an unstable ST segment, which experimental and
clinical data indicate reflects the patency of infarct-related
artery. In the clinical setting, it is difficult to accurately define
the variables that identify reperfusion because earlier studies
involved only a small series of patients and it is currently not
possible to perform routine coronary arteriography before and
after fibrinolytic treatment to identify with greater accuracy
those patients who have or have not achieved perfusion .
Blanke et al. (14) recognized total ST segment elevation as a
Group A
(n = 4,951)
Group B
(n = 2,475)
Odds Ratio
(95% CI)
Total (%)
(n = 7,426)
Ventricular fibrillation
266 (5
.4)
186 (7.5)
0.687 452 (6.1)
(0.561-0.841)
Sustained ventricular to chycardia
144 (29)
95(3.8)
0.741 239 (3.2)
(0.564-0.975)
Major AV block
469
(9.5)
229 (9.3) 1 .026 698 (9.4)
(0.869-1 .210)
Recurrence of infarction
102 (2.1) 46(l .9) 1 .108 148 (2.0)
(0.785-1 .565)
Early postinfarction angina 515 (10 .4) 193 (7.8) 1 .352 708 (9.5)
Group A
(n = 4,951)
Group B
(a - 2 .475)
Odds Ratio
(95% Cl)
Total (%)
(n = 7,426)
Total events
807 (16 .2) 568 (22 .9) 0.643
1,375 (18 .5)
(0.568-0 .728)
Deaths
164 (3.3)
181(7.3)
345 (4 .6)
Clinical heart failure
367 (7A)
208 (8.4) 575 (7 .7)
EF <35%
98(2.0) 68(2.7)
166
(2 .2)
Injured myocardial segment >45%
66(1 .3) 46(l .8)
112(l.5)
QRS sore
>10
112 (2.3)
65(2.6)
177 (2.4)
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Figure 2
. In-hospital mortality rate (num-
bers above bars) by percent reduction in
total ST segment elevation (F.ST) at 4 h
from symptom onset . Numbers within bars
are numbers of patients .
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more sensitive estimate of reperfusion than one-lead analysis,
and Hohnloser et al. (2) reported that the mean difference in
ST segment elevation between tracings recorded before and
after fibrinolytic therapy is -30% when patency of the infarct-
related artery has been achieved. Richardson et al. (15)
suggested that a significant decrease in or normalization of
total ST segment elevation is a good indicator of coronary
reperfusion (with a high positive predictive value), although
minimal or no changes do not rule out the recanalization of an
occluded vessel (low negative predictive value). Krucoff et al .
(16) showed in a pilot study that serial instantaneous assess-
ments of ST segment recovery using continuously updated
reference points appear to predict simultaneous infarct-related
Figure 3. Six-month survival rate in the two study groups .
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artery patency with 90% sensitivity and 92% specificity . The
suggested criteria refer to ST segment recovery as either a
reduction in ST elevation ?50% within 3 11 immediately
preceding peak ST segment elevation or a 35% to 49%
recovery in relation to the immediately preceding peak ST
segment elevation and ?50% recovery in relation to the most
abnormal ST segment peak documented at any time. The
speed, stability and duration of ST segment recovery do not
correlate with patency acutely defined by a single angiographic
procedure and appear to contain independent information,
probably because of patency changes before and after angiog-
raphy. Because of the instability of infarct-related artery
patency in the earlie. -hases of acute myocardial infarction,
we decided to examine the clinical meaning of a ?60%
reduction in total ST segment elevation, suggested by Bossaert
et al. (10) on the basis of data derived from an analysis of 103
patients as being a fairly useful predictor of patency as assessed
by coronary angiography 12 to 14 days after infarction (73%
sensitivity, 63% specificity, 88% positive predictive value) .
Electrocardiographic changes in different clinical settings.
The GISSI-2 trial is a randomized clinical trial that enrolled
>12,000 patients from the majority of Italian coronary care
units, most of which did not have catheterization laboratory
facilities. In the setting of this large-scale clinical trial, it was
shown that the early routine monitoring of ST segment reso-
lution represents a reliable and independent predictor of
immediate and long-term outcome in patients with acute
myocardial infarction treated with a fibrinolytic agent . Using
the cutoff value of a 50% decrease in the sum of ST segment
elevation, we obtained epidemiologic confirmation of patency
rates. The proportion of patients with a decrease >50% in
total ST segment elevation (66.7%) is consistent with the rates
< 70 < 80 <90 < 100 100
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reported by angiographic studies on the patency achieved with
either t-PA or streptokinase .
The slight difference in favor of streptokinase observed in
this large patient population confirms that, at least at 4 h,
streptokinase is not inferior to t-PA with respect to producing
ECG changes related to myocardial reperfusion and restora-
tion from ischemia, when the dosage and regimen adopted in
the GISSI-2 trial were used, and with heparin given subcuta-
;,eously >4 h . Recently published data from the Global
Utilization of Streptokinase and t-PA for Occluded Arteries
(GUSTO) trial (17) confirm that 3 h after the start of
treatment, the patency rate observed in the differently treated
groups had become equal . However, front-loaded t-PA plus
heparin, given intravenously in the GUSTO trial, seems to
achieve more rapid coronary reopening and consequently
more myocardial salvage than other therapeutic interventions .
Adjunctive calcium heparin therapy did not affect ECG evo-
lution whichever #ibrinolytic drug was used. The equivalence of
the treatments in terms of outcome (streptokinase or t-PA with
or without heparin with the dosage and modalities utilized in
GISSI-2) once again demonstrates that a spontaneous, late
change in reperfusion status (further reopening or reocclusion)
is not an infrequent event and is unrelated to the fibrinolytic
agent used with or without subcutaneous heparin . As in
angiographic studies, a single evaluation during the 1st 24 h
after acute myocardial infarction cannot be considered a
reliable marker of sustained reperfusion because of the inter-
mittency of the recanalization processes typical of the acute
phase of myocardial infarction. This could explain why the
slight difference in ECG responses in patients assigned to
different treatments does not affect in-hospital prognosis, as
indicated by the mortality rates, which were 4,8% in the
streptokinase group and 4 .5% in the t-PA group.
The equivalence of the thrombolytic treatments was also
confirmed in most patient subgroups, such as men and women,
young and old. Demographic and clinical variables do not seem
to affect ST segment alterations, with the sole exception of
insulin-dependent diabetic patients, who often show major
abnormalities in hemostatic and fibrinolytic factors (18), sug-
gesting a possible refractoriness to the action of thrombolytic
and antithrombotic agents .
From another perspective our study shows that early treat-
ment achieves more rapid ECG changes in infarcted tissue,
confirming the well-known correspondence between early
treatment and better prognosis . Early ST segment resolution is
less frequently seen in patients with anterior myocardial infarc-
tion and in those showing more compromised myocardial
function on admission (Killip class III or IV) . In these patients
lower systolic and diastolic blood pressures and higher preload
values can produce increased transmural stress and a reduction
in perfusion pressure that can hinder coronary reperfusion. In
addition, patients with an earlier decrease in total ST segment
elevation more frequently have peak serum CK levels <12 h,
thus reinforcing the hypothesis of earlier recanalization .
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Electrocardiographic changes after fibrinolysis and prog-
nosis . Malignant ventricular arrhythmias are significantly less
frequent in patients with an early decrease in total ST segment
elevation. This finding confirms that reperfusion associated
with early ECG changes leads to a better prognosis than
persistent ischemia with respect to the occurrence of major
arrhythmic events . By contrast, patients with earlier ST seg-
ment resolution more frequently develop postinfarction myo-
cardial ischemia .
The most striking finding of our study is the association
between the favorable resolution of ST segment elevation and
the 29% reduction in the cumulative end point of death and
left ventricular failure or severe dysfunction defined according
to the previously described hierarchic classification . This re-
duction concerns mortality rates, clinical signs of heart failure
and more compromised left ventricular function (ejection
fraction <35% ; injured myocardial segment >45%) . In addi-
tion to better survival, this also indicates a significant improve-
ment in the quality of life among surviving patients who show
an early resolution of ST segment elevation after thrombolytic
treatment. The relation observed between in-hospital mortality
and percent decrease in ST segment elevation is consistent
with that recently observed between mortality and degree of
infarct-related artery patency in the GUSTO study (17) .
The benefit observed in terms of mortality persists 6 months
after myocardial infarction . Adjusted analysis confirmed the
independent negative prognostic significance of a total ST
segment elevation reduction <50% at 4 h, and, therefore, our
data from a larger population also confirm the findings of the
Intravenous Streptokinase in Acute Myocardial Infarction
(ISAM) (19) and Estudio Multicenter Estreptoquinasa Repub-
licas Americas Sud (EMERAS) (20) trials, in which similar
noninvasive indicators of reperfusion were adopted .
We excluded patients with previous myocardial infarction
or bundle branch block from our first analysis because persis-
tent or secondary deviations of the ST segment could interfere
with the results . Yet in patients with a previous myocardial
infarction, the mortality rate was 5.3% and 13.4%, respectively,
in the two groups of patients with and without a ?50%
decrease in total ST segment elevation . Among the patients
with bundle branch block, the mortality rate was 16 .0% (57
patients) in the 356 patients with a >50% decrease in total ST
segment elevation versus 26.3% (64 patients) in the 243
patients without an early decrease in total ST segment eleva-
tion.
Conclusions. A simple, inexpensive instrumental evalua-
tion that was available in all participating centers and was not
affected by the epidemiologic and clinical characteristics of the
population allowed early assessment of the effectiveness of
(ibrinolytic treatment . In clinical practice, the possibility of
early prediction of outcome in terms of in-hospital clinical
events and long-term survival provides an opportunity for
planning adequate surveillance and diagnostic and interven-
tional programs aimed at further improving recanalization and
prognosis. In future, this noninvasive evaluation might prove to
be even more reliable than the angiographic assessment of
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patency widely used to compare different fibrinolytic and
antithrombotic regimens because of its close and well docu-
mented association with prognosis.
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